From published reports, a prioritized list ranking 75 tumor-associated vaccine antigens by these criteria is presented. Given the large number of potential tumor vaccine antigens, and the general ...

(2) These cells are activated using anti-CD3/CD28 antibodies to stimulate their proliferation. (3) Genetic modification of the T cells is performed by inserting the CAR gene, enabling them to ...

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological malignancies, is presenting clinical data from a ...

A new paper by a team of Concordia researchers from the departments of Biology and Physics proposes a novel method of ...

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

Chimeric antigen receptor-T (CAR-T) cell therapy ... We discuss the challenges such as immunosuppressive microenvironment, tumor heterogeneity, and physical barriers that limit CAR-T efficacy.

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Researchers have discovered that some CAR-T cells engineered to fight cancer and other conditions carry the memory of past encounters with bacteria, viruses and other antigens within them ...